<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03697746</url>
  </required_header>
  <id_info>
    <org_study_id>Pamukkkale University</org_study_id>
    <nct_id>NCT03697746</nct_id>
  </id_info>
  <brief_title>Comparison of Dexketoprofen, Paracetamol and Ibuprofen in the Treatment of Primary Dysmenorrhea</brief_title>
  <official_title>Comparison of Dexketoprofen, Paracetamol and Ibuprofen in the Treatment of Primary Dysmenorrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pamukkale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pamukkale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our study will be performed on 300 patients who meet the criteria for joining the emergency
      service with primary dysmenorrhea.

      3 drugs we will use: 1000 mg vial of paracetamol, dexketoprofen trometamol will be 50 mg
      ampoule and ibuprofen 400 mg vial

      According to the visual analog scale and visual visual scale, we will ask the patient to rate
      her pain between 0 (no pain) and 10 (the most severe pain of her life).

      We aim to determine the superiority of the drugs in passing the pain randomly by giving the 3
      drugs that we mentioned to patients with pain above 5.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our research will be carried out in Pamukkale University Faculty of Medicine Department of
      Emergency Medicine in 12 months period. There will be a research assistant and / or a faculty
      member who will control the research for 24 hours in our emergency department with
      approximately 110000 adult patients / year.

      Study criteria: Female patients with primary dysmenorrhea (abdomino-pelvic pain) in the 18-45
      age range. The onset of symptoms should usually be a few hours - 1 day before the onset of
      visible vaginal bleeding. Possible systemic symptoms such as nausea, vomiting, diarrhea,
      headache, fatigue, irritability, and dizziness are also questioned and recorded in the data
      form. Patients with a Visual Analog Scale &gt; 5 and those who require or are recommended
      nonsteroid antiinflammatory treatment.Patients who come with dysmenorrhea will be randomly
      selected and will be divided into three groups according to the pre-planned drug
      administration.

      Group 1; Paracetamol 1000 mg Group 2; Dexketoprofen Trometamol 50mg Group 3; Ibuprofen 400 mg
      In the form of group to be administered intravenously. In case of unresponsiveness to
      treatment, intravenous Tramadol hcl 100mg will be administered after 45 minutes.

      Pain scores of patients will be recorded using the Visual Analog Scale, 0-10 cm Visual Analog
      Scale, to score the degree of pain.During the process, O2 saturation monitorization,
      automatic manometer (blood pressure), rhythm monitorization (speed and rhythm) will be
      provided and all other medications during the operation will be recorded.

      Pain scores will be recorded at 0, 15, 30, 45 and 60 minutes. In addition, heart rate,
      systolic blood pressure, diastolic blood pressure, respiration rate and O2 saturation (SPO2)
      will be recorded at 0, 15, 30, 60 minutes.

      In addition, any side effects that may occur are recorded in the data sheet. If side effects
      are necessary, treatment will be applied. All information will be saved to the created work
      form
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ıtem pain intensity measure</measure>
    <time_frame>1 hour</time_frame>
    <description>the patient will be given medication and will be asked to score between 0 and 10 on a visual analog scale.(0=no pain, 10= pain as bad as can be) every 15 minutes within 1 hour</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ıtem pain intensity measure</measure>
    <time_frame>15 minute</time_frame>
    <description>100 mg of tramadol hcl will be given when the patient's pain does not fall below 5 points on a visual analog scale.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Dysmenorrhea</condition>
  <arm_group>
    <arm_group_label>Paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000 mg Paracetamol vial intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexketoprofen Trometamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mg Dexketoprofen Trometamol vial intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 mg Ibuprofen vial intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol</intervention_name>
    <description>paracetamol 1000 mg vial</description>
    <arm_group_label>Paracetamol</arm_group_label>
    <other_name>Parol 1000 mg vial--Mefar medicine-İstanbul</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexketoprofen Trometamol</intervention_name>
    <description>dexketoprofen trometamol 50 mg bulb</description>
    <arm_group_label>Dexketoprofen Trometamol</arm_group_label>
    <other_name>Dexiren 50 mg bulb-İlko medicine-İdol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>ıbuprofen 400 mg vial</description>
    <arm_group_label>Ibuprofen</arm_group_label>
    <other_name>İntrafen 400mg/4ml flakon-Gen medicine- Ankara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients with primary dysmenorrhea (abdomino-pelvic pain) between the ages of
             18-45.

          -  The onset of symptoms should usually be a few hours - 1 day before the onset of
             visible vaginal bleeding.

          -  Possible systemic symptoms such as nausea, vomiting, diarrhea, headache, fatigue,
             irritability, and dizziness are also questioned and recorded in the data form.

          -  Patients with visual analogue scale score&gt; 5 and those who need or need nonsteroidal
             anti-inflammatory treatment.

        Exclusion Criteria:

          -  Severe liver, kidney and heart failure; asthma, nasal polyp, angioedema and urticaria
             against aspirin or other nonsteroidal antiinflammatory drugs;

          -  Active peptic ulcer, bleeding or perforation; to have a history of upper
             gastrointestinal disease;

          -  Patients with phenylketonuria;

          -  During pregnancy and lactation;

          -  Have asthma;

          -  Have taken analgesics in the last 4 hours;

          -  The age of pregnancy and not using birth control method; digoxin, lithium, furosemide
             and other diuretics, acetylsalicylic acid and coumarin group using anticoagulants and
             physical examination of the suspicion of acute abdomen and signs of peritoneal
             irritation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SEÇKİN ÇİFTÇİOĞLU</last_name>
    <role>Principal Investigator</role>
    <affiliation>PAMUKKALE UNİVERSİTY HOSPİTAL EMERGENCY MEDİCİNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SEÇKİN ÇİFTÇİOĞLU</last_name>
    <phone>05550619591</phone>
    <email>seckinozyer@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>BÜLENT ERDUR</last_name>
    <phone>296-6312</phone>
    <phone_ext>258</phone_ext>
    <email>berdur@pau.edu.tr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pamukkale University</name>
      <address>
        <city>Deni̇zli̇</city>
        <zip>20160</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <contact>
      <last_name>SEÇKİN ÇİFTÇİOĞLU</last_name>
      <phone>05550619591</phone>
      <email>seckinozyer@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>BÜLENT ERDUR</last_name>
      <phone>296-6312</phone>
      <phone_ext>258</phone_ext>
      <email>berdur@pau.edu.tr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Letzel H, Mégard Y, Lamarca R, Raber A, Fortea J. The efficacy and safety of aceclofenac versus placebo and naproxen in women with primary dysmenorrhoea. Eur J Obstet Gynecol Reprod Biol. 2006 Dec;129(2):162-8. Epub 2006 May 3.</citation>
    <PMID>16675091</PMID>
  </reference>
  <reference>
    <citation>Ayan M, Taş U, Söğüt E, Arıcı S, Karaman S, Esen M, Demirtürk F. [Comparing efficiencies of diclofenac sodium and paracetamol in patients with primary dysmenorrhea pain by using Visual Analog Scale]. Agri. 2013;25(2):78-82. doi: 10.5505/agri.2013.42103. Turkish.</citation>
    <PMID>23720082</PMID>
  </reference>
  <reference>
    <citation>Iacovides S, Baker FC, Avidon I. The 24-h progression of menstrual pain in women with primary dysmenorrhea when given diclofenac potassium: a randomized, double-blinded, placebo-controlled crossover study. Arch Gynecol Obstet. 2014 May;289(5):993-1002. doi: 10.1007/s00404-013-3073-8. Epub 2013 Nov 5.</citation>
    <PMID>24190696</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 30, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <last_update_submitted>October 4, 2018</last_update_submitted>
  <last_update_submitted_qc>October 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pamukkale University</investigator_affiliation>
    <investigator_full_name>seçkin çiftçioğlu</investigator_full_name>
    <investigator_title>Emergency Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Dexketoprofen trometamol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcome measures will be made available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>data will be available within 1 year of study completion</ipd_time_frame>
    <ipd_access_criteria>data access requests will be reviewed by on external independent review panel requestors will be required to sign a data access agreement</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

